Gold bars to be exempt from tariffs, White House clarifies
On June 11, 2025, Janux Therapeutics, Inc., a biotechnology company currently valued at $1.48 billion, conducted its 2025 Annual Meeting of Stockholders. The meeting occurred amid challenging market conditions, with the stock down over 58% in the past six months according to InvestingPro data. The meeting saw the election of three Class I directors, ratification of the company’s independent registered public accounting firm, approval of executive compensation, and the frequency of future stockholder votes on executive pay.
The elected Class I directors, who will serve until the 2028 Annual Meeting, are David Campbell, Ph.D., Ron Barrett, Ph.D., and Winston Kung. The voting results for the director elections were as follows: Campbell received 44,740,538 votes for and 9,631,829 votes withheld, Barrett had 44,005,362 votes for and 10,367,005 votes withheld, and Kung received 42,187,543 votes for and 12,184,824 votes withheld. All three had 1,866,944 broker non-votes each. These directors will oversee a company that InvestingPro analysis shows maintains strong liquidity with a current ratio of 58.47, though it faces profitability challenges in the near term.
In addition, stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 56,152,990 votes for, 27,381 against, and 58,941 abstentions.
The compensation of the named executive officers was approved on an advisory basis, with 53,205,989 votes for, 1,150,947 against, and 15,431 abstentions, accompanied by 1,866,944 broker non-votes.
Lastly, stockholders favored holding future advisory votes on executive compensation every year with 53,985,296 votes for 1 year, 3,614 for 2 years, and 288,765 for 3 years, alongside 94,692 abstentions and 1,866,944 broker non-votes.
The information in this article is based on a press release statement. Looking ahead, InvestingPro data indicates the company’s next earnings report is scheduled for August 12, 2025, where analysts will be watching closely for signs of improvement in the company’s financial metrics. InvestingPro subscribers have access to 10 additional key insights about Janux Therapeutics, including detailed analysis of its financial health and growth prospects.
In other recent news, Janux Therapeutics has initiated a Phase 1b trial for its prostate cancer therapy, targeting metastatic castration-resistant prostate cancer (mCRPC). This follows positive results from a Phase 1a trial, which showed a median radiographic progression-free survival of 7.5 months. The Phase 1b study will further assess the safety and efficacy of JANX007, testing two dosing regimens. Meanwhile, Leerink Partners adjusted Janux Therapeutics’ price target from $91.00 to $89.00, maintaining an Outperform rating, reflecting continued optimism in the company’s cancer treatment approach. Leerink noted the potential impact of upcoming Phase 1 updates on Janux’s lead product, JANX007, and highlighted the significance of additional data for JANX008 expected in 2025. Janux plans to initiate further Phase 1b studies to evaluate JANX007 in various settings, aiming to support future registrational studies. The company also announced plans for an R&D Day in mid-2025 to discuss its progress and strategic priorities. Janux’s proprietary platforms have produced multiple candidates, with the first two targeting PSMA and EGFR in clinical trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.